VEGFA and neoplasm: Here, we demonstrate for the first time that anti-VEGF(R) treatment lowers IFP in peritoneal CRC xenografts, that this facilitates the diffusion and penetration of intraperitoneal Oxaliplatin, and that this results in greater tumor growth delay.